Premium
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo‐APP translation and processing
Author(s) -
YogevFalach Merav,
BarAm Orit,
Amit Tamar,
Weinreb Orly,
Youdim Moussa B. H.
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.05-4910fje
Subject(s) - neuroprotection , rasagiline , pharmacology , chemistry , amyloid precursor protein , biochemistry , microbiology and biotechnology , biology , alzheimer's disease , parkinson's disease , medicine , disease
The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on multiple targets has stimulated the development of the bifunctional drug ladostigil (TV3326) [(N‐propargyl‐(3R) aminoindan‐5yl)‐ethyl methyl carbamate]. Ladostigil combines the neuroprotective effects of the antiparkinson drug rasagiline, a selective monoamine oxidase (MAO)‐B inhibitor, with the cholinesterase (ChE) inhibitory activity of rivastigmine in a single molecule, as a potential treatment for Alzheimer's disease (AD) and Lewy Body disease. Here, we assessed the dual effects of lodostigil in terms of the molecular mechanism of neuroprotection and amyloid precursor protein (APP) regulation/processing by using an apoptotic model of neuroblastoma SKN‐SH cells. Ladostigil dose‐dependently decreased cell death via inhibition of the cleavage and prevention of caspase‐3 activation (IC501.05 µM) through a mechanism related to regulation of the Bcl‐2 family proteins, which resulted in reduced levels of Bad and Bax and induced levels of Bcl‐2 gene and protein expression. We have also followed APP regulation/ processing and found that ladostigil markedly decreased apoptotic‐induced levels of holo‐APP protein without altering APP mRNA levels, suggesting a posttranscriptional mechanism. In addition, the drug‐elevated phosphorylated protein kinase C (pPKC) levels and stimulated the release of the nonamyloidogenic ‐secretase proteolytic pathway. Similar to ladostigil, its S‐isomer, TV3279, which is a ChE inhibitor but lacks MAO inhibitory activity, exerted neuroprotective properties and regulated APP processing, indicating that these effects are independent of MAO inhibition.—Yogev‐Falach, M., Bar‐Am, O., Amit, T., Weinreb, O., Youdim, M. B. H. The multifunctional neuroprotective anti‐Alzheimer/ anti‐Parkinson drug ladostigil (TV3326) regulates holo‐APP translation and processing. FASEB J. 20, E1610 –E1618 (2006)